Roche Holding Ltd RO

The global biomarkers market is projected to grow from USD 67.95 billion in 2026 to USD 112.10 billion by 2031, registering a 10.5% CAGR. Growth is driven by precision medicine, companion diagnostics, AI, bioinformatics, digital pathology and multi-omics technologies. Predictive biomarkers led the efficacy segment in 2025, while immunoassays held the largest technology share. Asia Pacific is forecast to be the fastest-growing region. Key players include Roche, Abbott, Thermo Fisher Scientific, Q

The global disposable medical device sensors market is projected to grow from USD 11.86 billion in 2026 to USD 16.13 billion by 2031, registering a 6.4% CAGR. Growth is driven by chronic and infectious diseases, remote patient monitoring, point-of-care diagnostics, wearable devices, home healthcare, and infection-prevention needs. Biosensors currently lead the market, while strip sensors are expected to gain the largest share. The US will record North America’s highest CAGR. Key players include

New real-world results for Vabysmo in nAMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals1-3Advanced AI-enabled analysis of imaging confirms rapid and meaningful anatomical drying supporting Vabysmo as a standard-of-care therapy in routine clinical care4,5With more than 5,000 patients enrolled, VOYAGER is the largest, prospective, non-interventional real-world dataset evaluating Vabysmo across diverse clinical p

SOUTH SAN FRANCISCO, Calif., October 01, 2026--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the VOYAGER study evaluating the effectiveness, durability and safety of Vabysmo® (faricimab-svoa) in wet age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Across all study cohorts, results confirm the real-world effectiveness of Vabysmo in line with Phase III trial results, w

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimus1By targeting resistance to endocrine treatments, the giredestrant combination seeks to delay disease progression and improve overall patient outcomes1The FDA has set a PDUFA goal date for giredestrant in early-stage breast cancer of 30 November 2026 and in advanced disease of 18 December 2026 Basel, 1 Oct

SOUTH SAN FRANCISCO, Calif., October 01, 2026--evERA results published in The New England Journal of Medicine underscore the potential of investigational giredestrant in ER+ advanced breast cancer.

The FDA has accepted fenebrutinib for priority review across two forms of multiple sclerosis following three Phase III studies, moving Roche toward a potential expansion of its MS portfolio beyond Ocrevus. Key Investor TakeawaysGenentech, part of Roche Group (USOTC:RHHBY), has received FDA priority review for fenebrutinib in both relapsing multiple sclerosis and primary progressive multiple sclerosis.

Roche is increasingly looking like a notable contender in this fast-growing area.

Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix® Newborn TREC/SMN1/HBB kit, an in vitro diagnostic test for newborn screening in countries accepting the CE mark. The test simultaneously screens for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD). This launch provides a crucial, ready-to-use solution for private and academic hospital labs, enabling the ea

Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in delaying disability1Fenebrutinib became the first investigational medicine in more than a decade to slow disability progression in a Phase III PPMS trial (FENtrepid), with numerical benefit vs Ocrevus2Fenebrutinib is designed to address two drivers of MS – acute inflammation causing relapses and chronic brain inflammation driving disability progression1

SOUTH SAN FRANCISCO, Calif., September 30, 2026--FDA accepts filing for fenebrutinib, an investigational BTK inhibitor, for relapsing (RMS) and primary progressive (PPMS) multiple sclerosis.

SAN FRANCISCO & NEW YORK, September 29, 2026--Longevica forms a star SAB to turn its $13M, 16k-subject mammalian study into AI-driven drug discovery, pet health, and novel human therapies.

“BCC Research examines how AI is improving biomarker detection, ctDNA analysis, early cancer diagnosis and disease monitoring while advancing precision oncology and clinical decision-making.”Boston, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is fundamentally reshaping the liquid biopsy landscape, transforming blood-based cancer diagnostics from a promising concept into a clinically deployable, commercially scalable precision oncology tool. BCC Research's latest analysis, AI Impac

Graphwise, a leading provider of AI context platforms, today announced major updates to its AI Context Platform, Graphwise Platform, which include new Adobe integration, built-in evaluation tools, and broader workflow automation features. The new release optimizes the creation of a comprehensive context layer for enterprises, which accelerates the integration of AI into multilingual content and data. With its latest software release, Graphwise now supports its customers more efficiently when tra

SOUTH SAN FRANCISCO, Calif., September 28, 2026--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today broke ground on a $750 million expansion of its manufacturing facility in Hillsboro, Oregon, advancing plans announced in August to increase capacity for advanced drug delivery devices and to strengthen the company’s United States manufacturing capabilities. The event marks the start of construction for the 211,000-square-feet expansion, doubling the size of the existing si

Roche’s push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body weight in a mid-stage trial. The results add another potentially important asset to Roche’s efforts to challenge obesity-market […]

MRK and Daiichi withdraw an FDA filing for ifinatamab deruxtecan after data falls short, while late-stage studies continue.